Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2023-04-26 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司2022年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the 2022 annual financial settlement report of Jiangsu Sihuan Bio Co., Ltd. It contains detailed financial data for the year 2022, including income, profit, asset composition, cash flow, revenue, and cost breakdowns. It mentions that the financial statements have been audited by a CPA firm with an unqualified opinion including an emphasis of matter paragraph. The document also states that the report has been approved by the board and will be submitted to the shareholders' meeting for approval. The length is 4269 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or certification. This matches the characteristics of an Annual Report (10-K) or a full-year financial report. Given the detailed financial statements and audit information, this is best classified as an Annual Report (10-K). FY 2022
2023-04-26 Chinese
江苏四环生物股份有限公司关于2022年度计提资产减值准备及核销资产的公告
Audit Report / Information Classification · 95% confidence The document is an announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the 2022 annual asset impairment provisions and asset write-offs. It details the accounting policies and calculations for impairment losses on various asset categories, including bad debts, inventory, intangible assets, and other non-current assets. The document includes specific financial figures and explanations of impairment testing methods. It also states that the impairment provisions have been audited by Zhongshen Asia Pacific CPA firm. The document length is 3596 characters, which is relatively short but contains substantive financial data and detailed accounting explanations, not merely an announcement of a report or a certification. It is not a full annual report (10-K) but rather a specific audit-related disclosure about asset impairment provisions. This fits best under the category of Audit Report / Information (AR), which covers standalone audit reports and accounting principle applications excluding full annual reports. Therefore, the classification is AR with high confidence. FY 2022
2023-04-26 Chinese
江苏四环生物股份有限公司营业收入扣除事项的专项审核报告
Regulatory Filings
2023-04-26 Chinese
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2022 from Jiangsu Sihuan Bio Co., Ltd. It details the independent director's attendance at board meetings, opinions on various board resolutions, supervisory activities, and efforts to protect investor rights. The content focuses on the independent director's duties and oversight rather than financial results or audit opinions. It is not a full annual report, audit report, or financial statement. It is a management-related report concerning board activities and governance oversight. Therefore, the document fits best under Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports on their duties.
2023-04-26 Chinese
江苏四环生物股份有限公司董事会对带强调事项段无保留意见审计报告的专项说明
Audit Report / Information Classification · 95% confidence The document is an audit report explanation issued by the board of directors of Jiangsu Sihuan Bio Co., Ltd. It discusses an auditor's report with an emphasis paragraph (highlighting a legal case and its uncertain impact on profits) issued by Zhongshen Asia Pacific CPA firm for the fiscal year 2022. The document contains detailed explanations about the emphasis of matter paragraph in the audit report and the board's agreement with the auditor's opinion. It is not a full annual report but a standalone audit report or explanation related to the audit findings. The document length is under 5,000 characters and contains substantive audit-related content, not just an announcement or certification. Therefore, it fits best under the category Audit Report / Information (AR). FY 2022
2023-04-26 Chinese
独立董事关于2022年度报告有关事项的事前认可
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors providing prior approval on matters related to the 2022 annual report, including the reappointment of the audit firm and related party transactions. It is a formal attestation or certification related to governance and audit matters, but it does not contain the full annual report or detailed financial data. The document is short (462 characters) and serves as a regulatory or governance filing rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS).
2023-04-26 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.